Today 33 European academic partners and 5 pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance research programme New Drugs 4 Bad Bugs (ND4BB).

See original article:
COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB